ULTRALIFE Details Executive Equity Awards in Latest Proxy Filing
Ticker: ULBI · Form: DEF 14A · Filed: May 27, 2025 · CIK: 875657
| Field | Detail |
|---|---|
| Company | Ultralife Corp (ULBI) |
| Form Type | DEF 14A |
| Filed Date | May 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Executive Compensation, Proxy Statement, Equity Awards, Corporate Governance, DEF 14A, SEC Filing, ULTRALIFE CORP
Related Tickers: ULBI
TL;DR
**ULBI's proxy filing shows execs are heavily tied to equity, signaling a long-term play, but watch for actual performance numbers.**
AI Summary
ULTRALIFE CORP's DEF 14A filing, dated May 27, 2025, primarily details executive compensation for the fiscal years ending December 31, 2022, 2023, and 2024. The filing highlights equity awards for key executives, including Mr. Manna, President and CEO, and Mr. Fain, CFO, Treasurer, and Secretary. For Mr. Manna, equity awards in the summary compensation table were reported for 2022, 2023, and 2024. Similarly, Mr. Fain's equity awards were also detailed for the same periods. The document outlines changes in fair value of outstanding and unvested equity awards granted in prior years, as well as the year-end fair value of equity awards granted in the covered year that remain outstanding and unvested. Specific dollar amounts for these awards are not explicitly provided in the excerpt, but the structure indicates a focus on long-term incentive compensation through equity. The filing does not contain information on revenue, net income, or specific business changes, focusing instead on governance and executive remuneration ahead of the July 16, 2025, period of report.
Why It Matters
This DEF 14A filing is crucial for investors as it provides transparency into ULTRALIFE CORP's executive compensation structure, particularly the reliance on equity awards for its President and CEO, Mr. Manna, and CFO, Mr. Fain. Understanding how executives are incentivized can shed light on their alignment with shareholder interests and long-term company performance. In a competitive landscape, attracting and retaining top talent through effective compensation packages is vital, and this filing offers a glimpse into ULTRALIFE's strategy. Employees and customers might indirectly benefit from strong leadership incentivized for growth, while the broader market gains insight into governance practices within the miscellaneous electrical machinery sector.
Risk Assessment
Risk Level: low — The filing is a standard DEF 14A proxy statement, primarily detailing executive compensation, which inherently carries a low direct risk. It does not disclose new operational risks, financial distress, or significant strategic shifts. The information presented is routine for corporate governance, focusing on equity awards for Mr. Manna and Mr. Fain across 2022-2024.
Analyst Insight
Investors should scrutinize the full DEF 14A for the specific dollar values of these equity awards and compare them against ULTRALIFE's financial performance over the 2022-2024 period. This will help assess if executive compensation is appropriately aligned with shareholder returns and company growth. Pay close attention to vesting schedules and performance conditions attached to these equity grants.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Mr. Manna | President and CEO | |
| Mr. Fain | CFO, Treasurer and Secretary |
Key Numbers
- 2025-05-27 — Filing Date (Date the DEF 14A was filed with the SEC)
- 2025-07-16 — Conformed Period of Report (The period to which the proxy statement relates)
- 2024-12-31 — Fiscal Year End (Latest fiscal year for which executive compensation data is presented)
- 315-332-7100 — Business Phone (Contact number for ULTRALIFE CORP)
Key Players & Entities
- ULTRALIFE CORP (company) — Filer of DEF 14A
- Mr. Manna (person) — President and CEO of ULTRALIFE CORP
- Mr. Fain (person) — CFO, Treasurer, and Secretary of ULTRALIFE CORP
- SEC (regulator) — Recipient of DEF 14A filing
- Newark, NY (location) — Business address of ULTRALIFE CORP
- 2025-05-27 (date) — Filing date of DEF 14A
- 2025-07-16 (date) — Conformed period of report
- 0000875657 (identifier) — Central Index Key (CIK) for ULTRALIFE CORP
- 3690 (identifier) — Standard Industrial Classification (SIC) for ULTRALIFE CORP
- 1994-02-24 (date) — Date of name change from ULTRALIFE BATTERIES INC
FAQ
What is the purpose of ULTRALIFE CORP's DEF 14A filing?
ULTRALIFE CORP's DEF 14A filing, submitted on May 27, 2025, serves as a definitive proxy statement. Its primary purpose is to provide shareholders with information regarding matters to be voted upon at an upcoming meeting, specifically detailing executive compensation for Mr. Manna and Mr. Fain for the fiscal years ending December 31, 2022, 2023, and 2024.
Which executives are mentioned in ULTRALIFE CORP's DEF 14A regarding compensation?
The DEF 14A filing specifically mentions Mr. Manna, who holds the position of President and CEO, and Mr. Fain, who serves as CFO, Treasurer, and Secretary. The document details their equity awards and changes in fair value of these awards for the fiscal years 2022, 2023, and 2024.
What type of compensation is highlighted for ULTRALIFE CORP executives in this filing?
The filing primarily highlights equity awards as a significant component of executive compensation for Mr. Manna and Mr. Fain. It discusses the fair value of equity awards granted in prior years, changes in their fair value, and the year-end fair value of awards granted in the covered year that remain outstanding and unvested.
What fiscal years are covered for executive compensation in ULTRALIFE CORP's DEF 14A?
The DEF 14A filing covers executive compensation data for the fiscal years ending December 31, 2022, December 31, 2023, and December 31, 2024. This provides a three-year historical view of equity award grants and their valuation for key executives.
Where is ULTRALIFE CORP's business address located?
ULTRALIFE CORP's business address is listed as 2000 Technology Parkway, Newark, NY 14513. This information is provided in the header data of the DEF 14A filing.
What is ULTRALIFE CORP's Central Index Key (CIK)?
ULTRALIFE CORP's Central Index Key (CIK) is 0000875657. This unique identifier is used by the SEC to identify companies and individuals that file disclosure documents.
When was ULTRALIFE CORP's name changed from ULTRALIFE BATTERIES INC?
ULTRALIFE CORP's name was changed from ULTRALIFE BATTERIES INC on February 24, 1994. This historical detail is included in the former company information section of the filing.
What is the significance of the 'conformed period of report' date for ULTRALIFE CORP?
The 'conformed period of report' date of July 16, 2025, indicates the period for which the information in the DEF 14A is relevant, typically relating to the upcoming annual meeting of shareholders. This date is crucial for investors to understand the timeframe for which the proxy materials are prepared.
Does ULTRALIFE CORP's DEF 14A filing contain information about revenue or net income?
Based on the provided excerpt, ULTRALIFE CORP's DEF 14A filing does not contain specific information about revenue or net income. The excerpt focuses exclusively on executive compensation, particularly equity awards, and related fair value changes for Mr. Manna and Mr. Fain.
How can investors use the executive compensation data from ULTRALIFE CORP's DEF 14A?
Investors can use the executive compensation data from ULTRALIFE CORP's DEF 14A to evaluate the company's governance practices and how executive incentives align with shareholder interests. By analyzing the equity awards granted to Mr. Manna and Mr. Fain, investors can assess the long-term commitment of leadership and potential impact on future stock performance, especially when comparing compensation to company financial results.
Industry Context
ULTRALIFE CORP operates within the miscellaneous electrical machinery, equipment, and supplies sector. This industry is characterized by innovation in energy storage solutions and a competitive landscape driven by technological advancements and demand for specialized battery applications.
Regulatory Implications
As a publicly traded company, ULTRALIFE CORP is subject to SEC regulations governing financial reporting and executive compensation disclosures. Compliance with these regulations, including the accurate reporting in DEF 14A filings, is crucial to maintain investor confidence and avoid penalties.
What Investors Should Do
- Review executive compensation details to assess alignment with company performance and shareholder interests.
- Understand the structure and valuation of equity awards to gauge long-term incentive alignment.
- Note the filing date and period of report to stay informed about the company's governance and compensation practices.
Key Dates
- 2025-05-27: DEF 14A Filing Date — Indicates the official submission of the proxy statement to the SEC.
- 2025-07-16: Conformed Period of Report — The proxy statement pertains to this period, likely related to upcoming shareholder meetings or reporting cycles.
- 2024-12-31: Latest Fiscal Year End — Represents the end of the most recent fiscal year for which executive compensation data is presented in the filing.
Glossary
- DEF 14A
- A proxy statement filed by a company with the SEC detailing information about executive compensation, corporate governance, and matters to be voted on by shareholders. (This filing is the primary document for understanding executive pay and related corporate governance at ULTRALIFE CORP.)
- Equity Awards
- Forms of compensation granted to employees, typically executives, that are tied to the company's stock, such as stock options or restricted stock units. (A significant component of executive compensation for ULTRALIFE CORP's key personnel, as detailed in the filing.)
- Fair Value
- The estimated price at which an asset would change hands between a willing buyer and a willing seller, neither being under any compulsion to buy or to sell and both having reasonable knowledge of relevant facts. (Used to value the equity awards granted to executives, reflecting their potential worth.)
Year-Over-Year Comparison
This DEF 14A filing, dated May 27, 2025, focuses on executive compensation for fiscal years ending December 31, 2022, 2023, and 2024. Specific comparative metrics to a previous filing are not detailed in the provided excerpt, but the emphasis on equity awards suggests a consistent approach to long-term incentive compensation for key executives like Mr. Manna and Mr. Fain.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 27, 2025 by Mr. Manna regarding ULTRALIFE CORP (ULBI).